David J. Moliterno

Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction

Sorin J. Brener, Lawrence A. Barr, J.E.B. Burchenal et al. · Circulation · 1998 · 723 citations

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization

Eric J. Topol, David J. Moliterno, Howard C. Herrmann et al. · New England Journal of Medicine · 2001 · 678 citations · Full text

Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.

Koon‐Hou Mak, David J. Moliterno, Christopher B. Granger et al. · Journal of the American College of Cardiology · 1997 · 429 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +11

Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention

Steven R. Steinhubl, J. David Talley, Gregory A. Braden et al. · Circulation · 2001 · 358 citations

A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes

Sunil V. Rao, Kristi O’Grady, Karen S. Pieper et al. · Journal of the American College of Cardiology · 2006 · 306 citations

Thrombosis, Cardiovascular Disease, Atherosclerosis +14